PARPi and myeloid neoplasms; the Italian MITO-MaNGO experience based on a multicentric survey.

ABSTRACT:

Introduction

The introduction of poly (ADP-ribose) polymerase inhibitors (PARPi) in ovarian cancer has raised increasing concerns about PARPi-related myeloid neoplasms (PrMN). Therapy-related neoplasms, including myelodysplastic syndromes and acute myeloid leukemia, account for 10%-20% of cases. Expanding PARPi indications, longer survival, and aging populations may contribute to rising PrMN incidence. Randomized clinical trials and real-world analyses show a significant risk increase, but data on individual PARPi, treatment lines, and prior therapies are limited.

Methods

We evaluated PrMN incidence across 17 Italian centers using a 71-item survey distributed to MITO (Multicenter Italian Trials on Ovarian cancer) and MaNGO (Mario Negri Gynecologic Oncology) centers, focusing

SUBMITTER: Turinetto M 

PROVIDER: S-EPMC12670540 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature